| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.81B | +2.3% |
| Gross profit | ¥0.49B | — |
| Operating income | ¥0.13B | — |
| Net income | ¥0.13B | -13.5% |
| Gross margin | 60.4% | Net margin 15.8% |
| Revenue Q/Q | -25.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.32B | 39.6% |
| R&D | ¥0.13B | 16.4% |
| SG&A | ¥0.25B | 30.8% |
| Tax & other | ¥0.01B | 0.9% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
新劲刚 ・ 久吾高科 ・ 光莆股份 ・ 开立医疗 ・ 彩讯股份 ・ 中达安 ・ 同和药业 ・ 扬帆新材 ・ 广和通 ・ 凯普生物 ・ 德艺文创 ・ 正丹股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies